Victoria G. Empson

Vienna, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications

Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera.

Neutrophil-to-Lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera.

Journal: Blood cancer journal
Published: March 24, 2025

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Event-free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa-2b or hydroxyurea/best available therapy (PROUD-PV/CONTINUATION-PV).

Journal: HemaSphere
Published: January 28, 2025

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Journal: Annals of hematology
Published: January 12, 2024

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Journal: Leukemia
Published: May 15, 2023

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b.

Journal: Leukemia
Published: December 25, 2021

Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.

Human immunoglobulin (KIOVIG®/GAMMAGARD LIQUID®) for immunodeficiency and autoimmune diseases: an observational cohort study.

Journal: Immunotherapy
Published: April 14, 2015

A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.

A controlled trial of intravenous immunoglobulin in multifocal motor neuropathy.

Journal: Journal of the peripheral nervous system : JPNS
Published: January 21, 2013

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.

Journal: The Journal of allergy and clinical immunology
Published: November 30, 2011
Showing 1-8 of 8

Last Updated: 09/26/2026